MK Proteins Board of Directors
Get the latest insights into the leadership at MK Proteins. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Parvind Kumar | Chairman |
| Mr. Parmod Kumar | Managing Director |
| Mr. Vinod Kumar | Whole Time Director |
| Ms. Laxmi Mandal | Independent Director |
| Mr. Tej Mohan Singh | Independent Director |
| Mrs. Shipra Jain | Independent Director |
| Mr. Raj Kumar | Non Executive Director |
MK Proteins Share price
MKPL
6.71
0.01 (-0.15%)NSE
BSE
Last updated on 4 Nov, 2025 | 15:58 IST
BUYSELL
Today's High
6.80
Today's Low
6.70
52 Week Low
5.40
52 Week High
9.78
The current prices are delayed, login to your account for live prices
LoginMK Proteins FAQs
The board at MK Proteins consists of experienced professionals, including Mr. Parvind Kumar , Mr. Parmod Kumar , and others, overseeing the company’s strategic and corporate governance.
Directors at MK Proteins are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Parvind Kumar is the current chairman at MK Proteins.
Executive directors at MK Proteins are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, MK Proteins adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At MK Proteins, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.